Treatment outcomes for first localized, resectable recurrent retroperitoneal liposarcoma.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study that captures diagnostic details, treatments, complications, survival, and patient-reported quality of life from hospital records and questionnaires over five years. Participants form a validation cohort for the TARPSWG recurrent retroperitoneal sarcoma nomogram. Treatment (surgery alone or preoperative radiotherapy with or without chemotherapy followed by surgery) is determined by the institutional multidisciplinary sarcoma team. Quality of life is collected using the EORTC QLQ-C30 and OLO-STO22 at multiple time points, with each questionnaire taking about 15–20 minutes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)
2. No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease
3. Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only
4. Sarcoma not originating from bone or abdominal or gynecological viscera
5. Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)
6. WHO performance status 0-2
7. American Society of Anaesthesiologist (ASA) score 1-3
8. No prior RT for the retroperitoneal liposarcoma
9. Prior systemic therapy is allowed
10. No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)
11. Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment
12. Patient deemed able to comply with study requirements according to investigator evaluation
13. Signed, IRB-approved written informed consent

Exclusion Criteria:

1. Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team
2. Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible
3. Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease
4. Myxoid liposarcoma histology
5. Pregnancy

Where it's running

• Emory Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting
• OSU James Hospital
  Columbus, Ohio, United States Recruiting
• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Chris O'Brien Lifehouse
  Camperdown, New South Wales, Australia Recruiting
• Prince of Wales Hospital
  Randwick, New South Wales, Australia Recruiting
• Peter MacCallum Cancer Centre
  Melbourne, Victoria, Australia Recruiting

Study contacts

• Principal investigator: Angela Hong — Chris O'Brien Lifehouse
• Study coordinator: Janina Chapman
• Email: janina.chapman@petermac.org
• Phone: 61414316490

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exploring genetic factors in retroperitoneal liposarcoma recurrences

  This study is trying to see if changes in the fat around a type of cancer called retroperitoneal liposarcoma can help explain why it comes back after treatment.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT06436846

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.